At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 130 target
Drug / intervention
ZG005 Powder for Injection +1 moredrug
Likely dose
Donafenib Tosilate Tablets 0.2gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06239298Phase 2RecruitingMonitorUpdated 24mo ago · Completion was 4mo agoSlow Enrollment
Monitor
A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
In Brief
A Phase 2 clinical trial evaluating ZG005 Powder for Injection and Donafenib Tosilate Tablets for Solid Tumor. Currently recruiting, targeting 130 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
202420252026
First PostedFeb 2024
Enrollment StartMay 2024
Primary CompletionMar 2026
Study CompletionMay 2026
TodayJul 2026
First PostedFeb 2, 2024
Enrollment StartMay 10, 2024
Primary CompletionMar 1, 2026
Study CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 2.4 years ago
Interventions
ZG005 Powder for Injectiondrug
intravenous infusion(IV), once every 3 weeks
Donafenib Tosilate Tabletsdrug
The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage